LivaNova PLC
LIVNHealthcareNASDAQMedical Devices
Scan Results
Daily timeframeLivaNova PLC, a medical technology company, designs, develops, manufactures, markets, and sells products, therapies, and services in the United States, the United Kingdom, Germany, France, Italy, the. Valued at $4.43B, LIVN is a mid-cap name in its sector. The company operates in two segments, Cardiopulmonary and Neuromodulation.
Market Cap
$4.43B
Beta
0.86
P/E (TTM)
41.60
P/E (Fwd)
17.42
EPS (TTM)
$1.94
EPS (Fwd)
$4.63
ROE
9.5%
ROA
5.3%
Cash
$539.7M
Total Debt
$343.4M
Free CF
$198.1M
52W Change
92.2%
Annual Financials
Cash vs Debt
LivaNova PLC holds $539.7M in cash against $343.4M in total debt, giving it a net cash position. This means the company could theoretically pay off all its debt and still have cash remaining. Free cash flow comes in at $198.1M, providing flexibility for reinvestment, buybacks, or dividends. Consistent free cash flow generation is often considered a sign of operational health. Return on equity stands at 9.5%, which is decent for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. An ROA of 5.3% suggests reasonable efficiency in deploying the company's asset base. Revenue has grown from $1.02B (2022) to $1.39B (2025), reflecting a 36% increase over the period.
Investors considering LivaNova PLC should weigh the typical risks associated with LIVN's sector, size, and financial profile against their own risk tolerance and investment objectives. These risk factors are not exhaustive — macroeconomic shifts, regulatory changes, and competitive dynamics can all influence LivaNova PLC's trajectory.